Search results for "Opioids"
Q&A: DEA requires addiction training for all prescribers
The Drug Enforcement Administration is requiring eight hours of training related to substance use disorder treatment, sending clinicians scurrying to their continuing education providers for help.
https://immattersacp.org/archives/2023/05/dea-requires-addiction-training-for-all-prescribers.htm
1 May 2023
FDA considers new approach to safe disposal of opioids
This column reviews details on recent recalls, alerts, and approvals.
https://immattersacp.org/archives/2022/06/fda-considers-new-approach-to-safe-disposal-of-opioids.htm
1 Jun 2022
Mixing alcohol with opioids, benzodiazepines sending users to emergency departments
Nearly one-fifth of opioid abuse-related ED visits and more than one-fourth of benzodiazepine abuse-related ED visits involved alcohol, a study found.
https://immattersacp.org/weekly/archives/2014/10/21/1.htm
21 Oct 2014
Reproductive-age women widely prescribed opioid medications
Opioid-containing medications are widely prescribed among reproductive-age women with either private insurance or Medicaid, with approximately one-fourth of privately insured and more than one-third of Medicaid-enrolled women filling a prescription for an opioid each year from 2008 to 2012.
https://immattersacp.org/weekly/archives/2015/02/03/2.htm
3 Feb 2015
Guidance limited for treating acute pain
Prescribing a short-term opioid to patients who haven't recently or ever taken a controlled substance might boost their vulnerability to later addiction.
https://immattersacp.org/archives/2018/02/guidance-limited-for-treating-acute-pain.htm
1 Feb 2018
Deaths from stimulant use rose sharply in the past decade
Mortality from stimulants, including cocaine and methamphetamine, rose faster than deaths from opioids from 2010 to 2017, according to data from the National Center for Health Statistics.
https://immattersacp.org/weekly/archives/2021/02/09/4.htm
9 Feb 2021
ACP course helps prescribers safely prescribe opioids, meet FDA requirements
The FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for all brand and generic extended-release (ER) and long-acting (LA) opioid pain medicines to ensure that the benefits of prescribing a drug outweigh its risks for patients.
https://immattersacp.org/weekly/archives/2014/09/30/11.htm
30 Sep 2014
Pandemic may have led to changes in buprenorphine treatment initiation, retention
While more U.S. patients received buprenorphine for opioid use disorder between March 13 and Dec. 1, 2020, than during the same period in 2019, there were about 17% fewer new prescriptions than expected, a recent study found.
https://immattersacp.org/weekly/archives/2022/12/13/2.htm
13 Dec 2022
Calls to poison control centers for gabapentin, baclofen increased in recent years
The increase in exposures to and misuse of these medications in the U.S. may represent an unintended consequence of recent reductions in opioid prescribing for pain management, study authors said.
https://immattersacp.org/weekly/archives/2019/12/10/5.htm
10 Dec 2019
Primary care doctors do limited screening for misuse of long-term opioids
Primary care physicians' adoption of opioid risk reduction strategies is limited, even in treatment of patients at increased risk of misuse, a new study has found.
https://immattersacp.org/weekly/archives/2011/08/30/1.htm
30 Aug 2011